Literature DB >> 31558675

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.

Kristine A Frerichs1, Patricia W C Bosman1, Jeroen F van Velzen2, Pieter L A Fraaij3, Marion P G Koopmans3, Guus F Rimmelzwaan3, Inger S Nijhof1, Andries C Bloem2, Tuna Mutis1, Sonja Zweegman1, Niels W C J van de Donk4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31558675      PMCID： PMC7271608          DOI： 10.3324/haematol.2019.231860

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Competence and competition: the challenge of becoming a long-lived plasma cell.

Authors:  Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe
Journal:  Nat Rev Immunol       Date:  2006-09-15       Impact factor: 53.106

2.  Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours.

Authors:  M L Wumkes; A M T van der Velden; M Los; M B L Leys; A Beeker; M R Nijziel; A W G van der Velden; M Westerman; A Meerveld-Eggink; G F Rimmelzwaan; G T Rijkers; D H Biesma
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

3.  Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Authors:  Philippe Moreau; Michel Attal; Cyrille Hulin; Bertrand Arnulf; Karim Belhadj; Lotfi Benboubker; Marie C Béné; Annemiek Broijl; Hélène Caillon; Denis Caillot; Jill Corre; Michel Delforge; Thomas Dejoie; Chantal Doyen; Thierry Facon; Cécile Sonntag; Jean Fontan; Laurent Garderet; Kon-Siong Jie; Lionel Karlin; Frédérique Kuhnowski; Jérôme Lambert; Xavier Leleu; Pascal Lenain; Margaret Macro; Claire Mathiot; Frédérique Orsini-Piocelle; Aurore Perrot; Anne-Marie Stoppa; Niels Wcj van de Donk; Soraya Wuilleme; Sonja Zweegman; Brigitte Kolb; Cyrille Touzeau; Murielle Roussel; Mourad Tiab; Jean-Pierre Marolleau; Nathalie Meuleman; Marie-Christiane Vekemans; Matthijs Westerman; Saskia K Klein; Mark-David Levin; Jean Paul Fermand; Martine Escoffre-Barbe; Jean-Richard Eveillard; Reda Garidi; Tahamtan Ahmadi; Sen Zhuang; Christopher Chiu; Lixia Pei; Carla de Boer; Elena Smith; William Deraedt; Tobias Kampfenkel; Jordan Schecter; Jessica Vermeulen; Hervé Avet-Loiseau; Pieter Sonneveld
Journal:  Lancet       Date:  2019-06-03       Impact factor: 79.321

4.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-10-12       Impact factor: 17.586

5.  Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.

Authors:  Andrew R Branagan; Eamon Duffy; Randy A Albrecht; Dennis L Cooper; Stuart Seropian; Terri L Parker; Geliang Gan; Fangyong Li; Daniel Zelterman; Chandra Sekhar Boddupalli; Lin Zhang; Rakesh Verma; Thomas M Ferencz; Madhav V Dhodapkar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

6.  The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis.

Authors:  Mariëlle van Aalst; Annefleur C Langedijk; René Spijker; Godelieve J de Bree; Martin P Grobusch; Abraham Goorhuis
Journal:  Vaccine       Date:  2018-08-16       Impact factor: 3.641

7.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Authors:  Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; A Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson
Journal:  N Engl J Med       Date:  2015-08-26       Impact factor: 91.245

8.  Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Authors:  Jakub Krejcik; Kris A Frerichs; Inger S Nijhof; Berris van Kessel; Jeroen F van Velzen; Andries C Bloem; Marloes E C Broekmans; Sonja Zweegman; Johan van Meerloo; René J P Musters; Pino J Poddighe; Richard W J Groen; Christopher Chiu; Torben Plesner; Henk M Lokhorst; A Kate Sasser; Tuna Mutis; Niels W C J van de Donk
Journal:  Clin Cancer Res       Date:  2017-10-12       Impact factor: 12.531

9.  Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.

Authors:  Pamela L Clemens; Xiaoyu Yan; Henk M Lokhorst; Sagar Lonial; Nedjad Losic; Imran Khan; Richard Jansson; Tahamtan Ahmadi; Kristen Lantz; Honghui Zhou; Thomas Puchalski; Xu Steven Xu
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

10.  Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Authors:  Meletios A Dimopoulos; Jesus San-Miguel; Andrew Belch; Darrell White; Lotfi Benboubker; Gordon Cook; Merav Leiba; James Morton; P Joy Ho; Kihyun Kim; Naoki Takezako; Philippe Moreau; Jonathan L Kaufman; Heather J Sutherland; Marc Lalancette; Hila Magen; Shinsuke Iida; Jin Seok Kim; H Miles Prince; Tara Cochrane; Albert Oriol; Nizar J Bahlis; Ajai Chari; Lisa O'Rourke; Kaida Wu; Jordan M Schecter; Tineke Casneuf; Christopher Chiu; David Soong; A Kate Sasser; Nushmia Z Khokhar; Hervé Avet-Loiseau; Saad Z Usmani
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941
View more
  11 in total

1.  Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.

Authors:  Christie P M Verkleij; Marloes E C Broekmans; Mark van Duin; Kristine A Frerichs; Rowan Kuiper; A Vera de Jonge; Martin Kaiser; Gareth Morgan; Amy Axel; Rengasamy Boominathan; Jocelyn Sendecki; Amy Wong; Raluca I Verona; Pieter Sonneveld; Sonja Zweegman; Homer C Adams; Tuna Mutis; Niels W C J van de Donk
Journal:  Blood Adv       Date:  2021-04-27

Review 2.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

Review 3.  Immunotherapy for KSHV-associated diseases.

Authors:  Kathryn Lurain; Robert Yarchoan; Ramya Ramaswami
Journal:  Curr Opin Virol       Date:  2022-07-05       Impact factor: 7.121

Review 4.  COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.

Authors:  Joyce K Hwang; Tian Zhang; Andrew Z Wang; Zihai Li
Journal:  J Hematol Oncol       Date:  2021-02-27       Impact factor: 17.388

Review 5.  Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19.

Authors:  Michael R Yeaman
Journal:  Glomerular Dis       Date:  2021-08-25

6.  Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.

Authors:  Irit Avivi; Roi Balaban; Tamir Shragai; Gabi Sheffer; Miguel Morales; Anat Aharon; Noa Lowenton-Spier; Svetlana Trestman; Chava Perry; Noam Benyamini; Moshe Mittelman; Yaara Tabib; Tali Bar Lev; Mor Zavaro; Yair Herishanu; Efrat Luttwak; Yael C Cohen
Journal:  Br J Haematol       Date:  2021-07-01       Impact factor: 8.615

7.  Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.

Authors:  Roy Vitkon; Dan Netanely; Shai Levi; Tomer Ziv-Baran; Ronit Ben-Yzak; Ben-Zion Katz; Noam Benyamini; Svetlana Trestman; Moshe Mittelman; Yael Cohen; Irit Avivi
Journal:  Ther Adv Hematol       Date:  2021-07-28

8.  Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.

Authors:  Catarina Geraldes; Manuel Neves; Sérgio Chacim; Fernando Leal da Costa
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

Review 9.  Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.

Authors:  Hans-Hartmut Peter; Hans D Ochs; Charlotte Cunningham-Rundles; Donald C Vinh; Peter Kiessling; Bernhard Greve; Stephen Jolles
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793

10.  The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.

Authors:  Evangelos Terpos; Maria Gavriatopoulou; Ioannis Ntanasis-Stathopoulos; Alexandros Briasoulis; Sentiljana Gumeni; Panagiotis Malandrakis; Despina Fotiou; Eleni-Dimitra Papanagnou; Magdalini Migkou; Foteini Theodorakakou; Maria Roussou; Evangelos Eleutherakis-Papaiakovou; Nikolaos Kanellias; Ioannis P Trougakos; Efstathios Kastritis; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2021-08-02       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.